Health Care • Medical/Dental Instruments
$0.43 ▲ +0.02
(+5.03%)
MKT CAP: $87.9M • VOL: 5.06M
52W L $0 52W H $2
ROARABLE / RQD
D • 47/100
PIOTROSKI
2 / 9
LUCD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $4.3M | $2.4M |
| YoY Revenue Growth % | — | +79.0% | — |
| Gross Profit | — | -$2.8M | — |
| Gross Margin % | — | -50.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$49.6M | -$46.1M | -$48.5M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$58.0M | -$45.5M | -$52.7M |
| EBITDA (Normalized) | -$49.5M | -$45.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$46.5M | -$44.1M | -$32.8M |
| Capital Expenditures (CapEx) | $197.0K | $296.0K | — |
| Free Cash Flow (FCF) | -$46.7M | -$44.4M | -$32.8M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | — | $22.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $10.9M | $5.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LUCD.